%D9%81%D8%B1%D8%B7_%D9%86%D8%B4%D8%A7%D8%B7_%D8%A7%D9%84%D9%85%D8%AB%D8%A7%D9%86%D8%A9Hyperaktivn%C3%AD_mo%C4%8Dov%C3%BD_m%C4%9Bch%C3%BD%C5%99Overactive_bladderS%C3%ADndrome_de_vejiga_hiperactiva%D9%85%D8%AB%D8%A7%D9%86%D9%87_%D8%A8%DB%8C%D8%B4%E2%80%8C%D9%81%D8%B9%D8%A7%D9%84Hyperactivit%C3%A9_v%C3%A9sicale%D7%AA%D7%A1%D7%9E%D7%95%D7%A0%D7%AA_%D7%94%D7%A9%D7%9C%D7%A4%D7%95%D7%97%D7%99%D7%AA_%D7%94%D7%A8%D7%92%D7%99%D7%96%D7%94%D4%B3%D5%A5%D6%80%D5%A1%D5%AF%D5%BF%D5%AB%D5%BE_%D5%B4%D5%AB%D5%A6%D5%A1%D5%BA%D5%A1%D6%80%D5%AF%E9%81%8E%E6%B4%BB%E5%8B%95%E8%86%80%E8%83%B1%EA%B3%BC%EB%AF%BC%EC%84%B1_%EB%B0%A9%EA%B4%91%E0%AC%85%E0%AC%A4%E0%AC%BF%E0%AC%B8%E0%AC%95%E0%AD%8D%E0%AC%B0%E0%AC%BF%E0%AD%9F_%E0%AC%AE%E0%AD%82%E0%AC%A4%E0%AD%8D%E0%AC%B0%E0%AC%BE%E0%AC%B6%E0%AD%9FBexiga_hiperativa%D0%93%D0%B8%D0%BF%D0%B5%D1%80%D0%B0%D0%BA%D1%82%D0%B8%D0%B2%D0%BD%D1%8B%D0%B9_%D0%BC%D0%BE%D1%87%D0%B5%D0%B2%D0%BE%D0%B9_%D0%BF%D1%83%D0%B7%D1%8B%D1%80%D1%8C%C3%96veraktiv_bl%C3%A5saB%C3%A0ng_quang_ho%E1%BA%A1t_%C4%91%E1%BB%99ng_qu%C3%A1_m%E1%BB%A9cQ874632%E8%86%80%E8%83%B1%E9%81%8E%E5%8B%95%E7%97%87
about
Overactive bladder: strategies to ensure treatment compliance and adherenceIntravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract SurgeryBotulinum toxin A for the Treatment of Overactive BladderPersistence and compliance with medication management in the treatment of overactive bladderFundamentals and clinical perspective of urethral sphincter instability as a contributing factor in patients with lower urinary tract dysfunction--ICI-RS 2014Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an updateDrug therapy of overactive bladder--what is coming next?Local Oestrogen for Pelvic Floor Disorders: A Systematic ReviewOnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic reviewDoes fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?Overactive bladder - 18 years - Part ISolifenacin significantly improves all symptoms of overactive bladder syndrome.Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidenceTolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic reviewRefractory overactive bladder: a common problem?Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care.Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladderEfficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.Overactive bladder - 18 years - Part IITransdermal oxybutynin in the treatment of overactive bladder.Pharmacologic management of overactive bladder.Treatment of overactive bladder in the aging population: focus on darifenacin.Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin.The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderlyPreserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence.Basic mechanisms of urgency: roles and benefits of pharmacotherapyA short review of drug-food interactions of medicines treating overactive bladder syndrome.Profile of mirabegron in the treatment of overactive bladder: place in therapy.Recurring priapism may be a symptom of voiding dysfunction - case report and literature review.Clinical implications of underactive bladder.Acupuncture for adults with overactive bladder: A systematic review and meta-analysis of randomized controlled trials.Use of antimuscarinics in the elderly.Botulinum toxin use in the lower urinary tract.Understanding overactive bladder and urgency incontinence: what does the brain have to do with it?Concomitant primary ovarian paraganglioma neuroendocrinal differentiated urothelial tumor in a BOTOX-injected bladder: A case report
P921
Q26746914-1C02C8AB-3363-4D88-BBD2-F18AC196AB95Q26749608-7161F1E3-E233-4152-A2E9-7D42CAA17A1BQ26764765-82F5C21D-71FC-4966-A83B-D58D8FFD2D5AQ26765014-5DA5F63D-A709-4011-B91A-879A60062048Q26766221-043706BF-27E6-400B-8E17-ED7B191506B9Q26775925-56169EA7-2774-48E1-95DC-351322B2058EQ26780197-2B1D5E21-AF77-466E-88A5-EA04AF4D5915Q26783453-D6DECD59-E1E1-496F-A820-7956223D5664Q26826756-D1CF7B38-7095-42F5-BDE7-316C76CD2DE2Q27000698-B0EE4F42-F84B-4DB4-A800-35F3B9004140Q30388069-274618EF-0AC5-41E5-9CC1-765BFF58469AQ30445725-84BC0970-DAF8-4529-BA4B-0255C7749302Q30906698-9C7AF7D0-9636-41A7-AB21-8137630F1EBBQ34502903-4150C918-5244-4A37-95A8-13007239CE7EQ34569906-749E963D-A194-4CE5-BEB3-8DC3B3E1628EQ36073640-A5F04B7D-9F5A-4D63-A70E-729F9945026CQ36223634-CAD57B49-64D9-43AB-9178-38402F660D57Q36573132-09797BB4-067E-4EF3-B1A0-0476077F7FC4Q36804908-FCFD4838-3267-4FA8-9742-892E47A3B91CQ36912766-94D1AA7C-29ED-4F10-AA45-56F0EA9ABAD5Q37017359-3238B2B7-556E-4590-85CA-71C9449A7686Q37017434-6BD045D5-A497-4E44-86D9-C7EFAB4A91DCQ37018934-A2D1803F-D265-427C-959E-BAB79802796EQ37192944-B7873DE0-7A79-4827-9CE5-8E6CB0111B3BQ37199946-1427E03B-FB36-4BC2-83EC-3AE6886413F4Q37242704-A0862C61-8B80-47EA-B643-B1BB106F22A9Q37325841-4F9461A8-1F0A-416D-8F74-A3BC40317689Q37428717-11328236-0750-479E-8EA7-2F0EEAEB84C6Q37442137-55CEF746-89BA-42DE-A37E-4044A2B745CDQ37664787-B5280158-34ED-44EC-9600-665780782FA8Q38852077-51A643FA-F7E9-42AC-B3DF-634D881DEAF8Q47130067-00FE471A-C4F3-41BD-BB9A-FBFB5389FF6AQ49712145-97202878-3A29-4162-B69F-C939BAE7F182Q53101403-0D942C01-B0C3-4D6D-925C-71A4CB2C9434Q55193660-BFA1A1AB-FB12-40D9-AA6C-4DA1A76727EEQ60927243-D1F6E2B6-594F-4F31-A9AC-5A7AB0A22C9CQ64107606-1AF401A4-57C0-4E73-9F12-62B07107B773
P921
description
Krankheit
@de
human disease
@en
ανθρώπινη νόσος
@el
дисфункция нижних мочевыводящи ...... го рефлекса императивного типа
@ru
مرض يصيب الإنسان
@ar
name
Bàng quang hoạt động quá mức
@vi
bexiga hiperativa
@pt
hyperactivité vésicale
@fr
hyperaktivní močový měchýř
@cs
low compliance bladder
@en
síndrome de vejiga hiperactiva
@es
överaktiv blåsa
@sv
υπερδραστήρια κύστη
@el
гиперактивность мочевого пузыря
@ru
Գերակտիվ միզապարկ
@hy
type
label
Bàng quang hoạt động quá mức
@vi
bexiga hiperativa
@pt
hyperactivité vésicale
@fr
hyperaktivní močový měchýř
@cs
low compliance bladder
@en
síndrome de vejiga hiperactiva
@es
överaktiv blåsa
@sv
υπερδραστήρια κύστη
@el
гиперактивность мочевого пузыря
@ru
Գերակտիվ միզապարկ
@hy
altLabel
Low bladder compliance
@en
Low compliance bladder (disorder)
@en
Overactive bladder
@en
hyperactivity of bladder
@en
hypertonic bladder
@en
hypertonicity of bladder
@en
υπερλειτουργική κύστη
@el
ГАМП
@ru
ГМП
@ru
гиперактивный мочевой пузырь
@ru
prefLabel
Bàng quang hoạt động quá mức
@vi
bexiga hiperativa
@pt
hyperactivité vésicale
@fr
hyperaktivní močový měchýř
@cs
low compliance bladder
@en
síndrome de vejiga hiperactiva
@es
överaktiv blåsa
@sv
υπερδραστήρια κύστη
@el
гиперактивность мочевого пузыря
@ru
Գերակտիվ միզապարկ
@hy
P672
P486
P5806
P6366
P646
P1692
P1995
P279
P2888
P2892
P31
P3471
P3827
overactive-bladder
P486
P5270
MONDO:0001446
P5806
P6366
2781036200
2909219767
P646
/m/027hvwb
P672
C12.777.829.866
C13.351.968.829.813
C23.888.942.343.780
P699
DOID:12144